Vortex Energy Stock Quote VRTX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.105

Bid

0.105

Ask

0.11

Volume

106,528

0.10 Day's Range 0.11

0.10 52 Week Range 0.85

Previous Close

0.10

Open

0.11

Last Trade

1000

0.105

Last Trade Time

Average Volume (3m)

77,694

Financial Volume

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.005	-4.54545454545	0.11	0.125	0.1	82823	0.10845454	CS
4	-0.04	-27.5862068966	0.145	0.145	0.1	121623	0.11335112	CS
12	-0.105	-50	0.21	0.21	0.1	77694	0.14073489	CS
26	-0.17	-61.8181818182	0.275	0.275	0.1	70873	0.18144182	CS
52	-0.665	-86.3636363636	0.77	0.85	0.1	162311	0.42458118	CS
156	0.005	5	0.1	2.32	0.1	205975	0.97012957	CS
260	0.005	5	0.1	2.32	0.1	205975	0.97012957	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WRUNWaverunner Capital Inc	$ 0.01 (100.00%)	218.44k
ASTIAquarius Surgical Technologies Inc	$ 0.02 (100.00%)	1,000
VTALJustera Health Ltd	$ 0.01 (100.00%)	20.15k
PLNKPlank Ventures Ltd	$ 0.075 (87.50%)	27k
TAATTAAT Global Alternatives Inc	$ 0.31 (72.22%)	16.46k
GOHGoldHaven Resources Corp	$ 0.065 (-53.57%)	35.5k
BHCCBlue Horizon Global Capital Corp	$ 0.005 (-50.00%)	450k
MYNDMYND Life Sciences Inc	$ 0.01 (-50.00%)	4.72k
SLZSlave Lake Zinc Corp	$ 0.02 (-50.00%)	1.25k
NEWDNewfoundland Discovery Corp	$ 0.005 (-50.00%)	162k
LEXTLexston Mining Corporation	$ 0.09 (20.00%)	2.55M
LEEFLeef Brands Inc	$ 0.02 (-20.00%)	2.32M
FUTRGold n Futures Mineral Corp	$ 0.005 (0.00%)	2.26M
VRVictory Battery Metals Corp	$ 0.02 (33.33%)	1.1M
QIMCQuebec Innovative Materials Corp	$ 0.315 (6.78%)	1.03M